Allogene Therapeutics, Inc. (ALLO)
NASDAQ · Manufacturing · Biological products, (no diagnostic substances)
$1.65−$0.0200 (−1.20%) on the dayAs of the close; data may be delayed.
ALLO price, last 12 months
Key stats
- Previous close
- $1.67
- Open
- $1.69
- Day range
- $1.63 – $1.70
- 52-week range
- $1.04 – $4.46
- Volume
- 3.6M
- Avg volume (20 days)
- 5.6M
- Market cap
- $570.1M
Performance
1W−2.4%
1M−19.1%
3M−22.5%
6M−31.5%
YTD+20.4%
1Y+34.2%
vs S&P 500, 1Y+17.4 pts
Technicals and fundamentals
About Allogene Therapeutics, Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
- Sector
- Manufacturing
- Industry
- Biological products, (no diagnostic substances)
- Listed on
- NASDAQ
- Market cap
- $570.1M